gotistobart + lutetium Lu 177 vipivotide tetraxetan

This is a **combination drug** of gotistobart with lutetium Lu 177 vipivotide tetraxetan. Lutetium Lu 177 vipivotide tetraxetan is a radioligand therapeutic agent consisting of the radionuclide lutetium-177 linked to a ligand targeting prostate-specific membrane antigen (PSMA), a transmembrane protein overexpressed in prostate cancer cells. Once administered, the drug binds to PSMA-expressing cells and delivers beta radiation, causing DNA damage and cell death[1][2][5]. Gotistobart's identity and function are unclear from available sources; no evidence supports its use or mechanism, and it is not listed in recognized drug databases. The combination would, therefore, involve gotistobart plus a radiopharmaceutical agent approved primarily for PSMA-positive metastatic castration-resistant prostate cancer[1][2][3][5].

Other names

Pluvicto